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Elizabeth A Ashley1,2* and Nicholas J White1,2Abstract
Plasmodium vivax and Plasmodium ovale are often considered the malaria parasites best adapted to long-term
survival in the human host because of their latent exo-erythrocytic forms. The prevailing opinion until the middle of
the last century was that the maximum duration of Plasmodium falciparum infections was less than two years. Case
reports and series investigating blood donors following accidental malaria infection of blood transfusion recipients
and other sporadic malaria cases in non-endemic countries have shown clearly that asymptomatic P. falciparum
infections may persist for up to a decade or longer (maximum confirmed 13 years). Current policies in malaria-free
countries of excluding blood donors who have lived in malarious areas are justified. Vigilance for longer than three
years after declaring elimination in an area may be needed.
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Plasmodium vivax and Plasmodium ovale are often con-
sidered the malaria parasites best adapted to long-term
survival in the human host because of their latent exo-
erythrocytic forms. Yet Plasmodium malariae, which
has no latent forms, can persist asymptomatically in the
blood for decades, and perhaps throughout the entire
life of the host [1]. Many of these persistent asymptom-
atic P. malariae infections have been revealed by blood
donation [2], with illness in the recipient (but not the
donor). The maximum duration of asymptomatic infec-
tion is relevant both to transfusion risks and also in
planning and evaluating malaria elimination.
Characterization of the natural history of untreated or
partially treated Plasmodium falciparum malaria comes
first from the early descriptions of neurosyphilis patients
who were given malaria. Malariatherapy, the brainchild
of the Viennese neuropsychiatrist Julius Wagner-Jauregg,
was introduced as a treatment for neurosyphilis in the
1920s, and was widely used until supplanted by penicil-
lin in the 1950s. The malariatherapy parasite of choice
was generally P. vivax rather than the more dangerous
P. falciparum, but all species were used. Detailed studies
of syphilis patients infected with strains of P. falciparum* Correspondence: liz@tropmedres.ac
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unless otherwise stated.reported durations of infection between 50 and 500 days
depending on the infecting strain [3,4].
The duration of P. falciparum infections was debated by
malariologists during the first era of malaria eradication
(in the 1950s) as it was a key consideration in the investi-
gation of any sporadic cases in the post-elimination
period. A review by Covell in 1960 presented the prevail-
ing opinion that P. falciparum infections generally did not
continue beyond one year although he noted nine cases
where infection had recurred between one and two years
after the primary infection, and he cited Ciuca’s review of
12,842 cases of experimental malaria from Romania show-
ing a maximum persistence of P. falciparum infections of
27 months [5-7]. In 1964 Jacques Verdrager, a WHO mal-
ariologist, reviewed the literature again and added his own
observations from the Malaria Eradication Project in
Mauritius which suggested that P. falciparum could per-
sist in humans for at least three years. One example was
probable transfusion malaria from a donor who must have
been parasitaemic for more than two years. Another was a
presumed recrudescence of falciparum malaria in a young
woman who had a documented episode of malaria three
years previously, after which she had resided in an area
considered free of malaria transmission [8]. Cohort studies
in endemic areas have also proved informative. Between
1931 and 1934 in Puerto Rico, Earle followed a cohort of
71 schoolchildren prospectively with very frequent
blood sampling for microscopy and found that some P.
falciparum infections continued for up to 121 weeks [9].ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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estimate the duration of falciparum infections using re-
peated cross-sectional survey data from other cohorts,
such as the subjects in the Garki project in the 1970s.
Estimates for the total duration of infection across all
age groups were long at 602 days (95% confidence inter-
val (CI) 581–625) for Pare-Taveta (in Kenya/Tanzania),
734 days (95% CI 645–849) for West Papua, and
1,329 days (95% CI 1,193-1,499) for Garki in Nigeria
[10]. Until molecular genotyping was introduced it was
not possible to distinguish chronic single infections from
multiple repeated infections in endemic areas, suggesting
that the predicted longevity of blood stage infections
based on microscopy data might be overestimated. The
protracted duration of natural infections was demon-
strated in Eastern Sudan where 16 of 43 individuals who
had either had a malaria illness during the transmission
season or were PCR positive for P. falciparum malaria at
the end of the malaria season remained chronically in-
fected throughout the dry season and the following rainy
season with the same genotype [11].
In high-transmission areas asymptomatic parasitaemia
is very common. The ability of individuals to control
their parasitaemia at low levels without symptoms (pre-
munition) results from the gradual acquisition of im-
munity following repeated or protracted exposure. In
these areas uncomplicated and severe malaria are pre-
dominantly diseases of young children. Superinfection is
usual with individuals harbouring multiple, genetically
unrelated, parasite clones in a constantly changing equi-
librium, often generating transmissible densities of ga-
metocytes but remaining below the combined asexual
parasite density that provokes illness [12-14].
Hyperreactive malarial splenomegaly
Sometimes the host immune response to repeated malaria
infection is excessive, manifest by the syndrome of hyper-
reactive malarial splenomegaly (HMS); marked splenomeg-
aly with hypersplenism and hypergammaglobulinaemia (in
particular raised IgM). Plasmodium falciparum is usually
responsible. Anti-malarial antibody titres are high but mi-
croscopy examination of blood smears is usually negative.
Persistent or recurrent active malaria infection is con-
firmed by response (shrinkage of the spleen) to effective
anti-malarial treatment (often in a prolonged course to pre-
vent re-infection). Typical histopathological findings in the
spleen are non-specific cellular hyperplasia and lympho-
cytic infiltration without malaria pigment. Two cases of
symptomatic falciparum malaria occurring post splenec-
tomy (performed for suspected lymphoma) were reported
from France. Both were in immigrants who had not visited
a malaria-endemic area for at least two years. Their diagno-
ses were changed to HMS retrospectively and indicate per-
sistent active infection throughout this more than twoyears interval [15]. Similarly, a case report in Australia
described a 28-years-old woman, born and brought up in
Eritrea and Sudan, who developed falciparum malaria fol-
lowing splenectomy nine years after arriving in Australia.
Histopathological findings in the spleen were compatible
with HMS [16]. Examples of chronic falciparum infection,
such as these from non-endemic countries, are very in-
formative since the possibility of re-infection can be ex-
cluded with confidence. The richest source of information
on persistent malaria comes from reports of malaria in re-
cipients of blood transfusions or transplants in non-
endemic areas.Transfusion- and transplant-transmitted malaria
The first report of malaria as an accidental consequence of
an artery to vein blood transfusion was described in 1910
by Woolsey [17]. The efficiency of blood transfusion in
transmitting low density parasitaemias to naïve recipients
was exploited by Fairley in his classic studies of the biology
and chemotherapy of human malaria conducted in Cairns
in the 1940s [18]. Fairley also observed protracted infec-
tions in some of his volunteers. A review of transfusion
malaria published in 1974 summarized 2,001 cases of
transfusion-transmitted malaria between 1911 and 1972,
of which at least 88 were due to P. falciparum [19]. The
details of most of these cases are not in the public domain.
In those for whom information was available, the mean
time between the transfusion and the onset of symptoms
of malaria was 10.5 days (i.e., five asexual cycles) for the P.
falciparum cases. Assuming a multiplication factor of
approximately ten-fold per cycle and a pyrogenic thresh-
old of 108 parasites in total in an adult, this suggests an in-
oculum of ~1,000 parasites in a blood bag or bottle of
approximately 500 mL. Thus the likely donor density ap-
proximated an average of 2 parasites/mL, well below the
pyrogenic (and microscopy detection threshold) density
of ≥50,000/mL.Review
A search of Pubmed and Embase was performed for case
reports of transfusion or transplant transmitted falcip-
arum malaria or for cases of falciparum malaria present-
ing more than six months after leaving an endemic area.
Cited references were used to identify other cases. Cases
of transfusion-transmitted malaria from the USA were
searched for in the annual MMWR malaria surveillance
reports. Searches were also performed in websites of
blood banks and the international haemovigilance net-
work [20]. Reports of cases were excluded if the species
was described as ‘tertian’ malaria without further clarifi-
cation, if in languages other than English or French, or if
the probable duration of the infection in the case or
donor was six months or less.
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transmitted falciparum malaria are summarized in Table 1.
The time interval from last possible exposure to malaria
and the accidental transmission of the infection ranged
from six months to 13 years, but was less than two years
in half of the cases. However, this uses a very conservative
definition of the last time the donor was in an endemic
area as the time of acquisition, thus all the estimates here
are minimum possible estimates and very likely under-
estimates of true durations of infection. Donors included
immigrants from malaria-endemic countries and non-
immune donors who had acquired their malaria abroad,
e.g., soldiers. The time between the transfusion and the on-
set of symptoms varied between four days and four weeks.
This suggests a variety of inocula and multiplication rates
(Figures 1 and 2A).
Table 2 and Figure 2 summarize 32 cases of falciparum
malaria in individuals diagnosed between seven months
and 15 years after leaving a malaria endemic area. Plasmo-
dium falciparum gametocytaemia was reported in three of
the cases. In one case, gametocytes were the only parasite
stage seen on the blood film a month after a fever episode,
suggesting the patient had self-cured the infection. Five
cases reported having taken antimalarial drugs previously.
In 13 cases the symptomatic episode coincided with
pregnancy (seven women) or was associated with a co-
morbidity, e.g., diagnosis of malignancy (one), diabetes
mellitus (one), post head-injury (one), sickle-cell anaemia
(one), HIV (two cases), which suggests a reduction in host
immunity may have unmasked the latent infection.
Detection of occult malaria infections
The ability to detect asymptomatic carriers of malaria par-
asites depends on the sensitivity of the detection method
used. Blood smear microscopy by experienced microsco-
pists will detect parasite densities of ≥50/μL reliably. More
recently, molecular methods have been employed to de-
tect sub-patent parasitaemias. PCR is considerably more
sensitive than microscopy or rapid diagnostic tests based
on antigen detection but typically blood samples have
been taken from finger-prick blood spots on filter paper,
thus a volume of only ~5 μL has been amplified. This ob-
viously misses densities which are below one parasite in
5 μL or 200 parasites/mL. In general, most PCR methods
have limits of detection of ≥1,000 parasite/mL. Using lar-
ger blood volumes parasite densities down to ~20/mL can
be detected, several orders of magnitude below the mi-
croscopy level of detection [60].
Malaria infection may also be assessed using serology,
although interpretation is difficult. A variety of crude and
more refined test antigens have been evaluated. Typically
seroprevalence increases with age while the correlation
with patent parasitaemia goes down [61,62]. The usual
duration of positive malaria antibody responses once aninfection has been cleared with or without anti-malarials,
in the absence of ongoing exposure, and the specificity of
negative serology results to exclude active infection are
both uncertain.
Longitudinal serological studies have been conducted
in immigrants who have moved to countries that are
malaria free. In a Spanish study IgG antibody levels
against the erythrocytic antigens AMA-1 and MSP-142
(3D7 and FVO strains), EBA-175 and DBL-α, did not
correlate with the time since migration [63]. Serology
is used by a number of transfusion services for blood
donor screening. Between 2005 and 2011, in the USA,
5,610 malaria-deferred donors were tested by EIA, in-
cluding 5,412 travel deferrals. Overall, 88 (1.6%) of tests
were EIA reactive on repeat testing, none of which were
PCR positive [64]. In the transfusion-transmitted malaria
cases summarized in Table 1, 11 donors had positive ser-
ology between ten months and 13 years after leaving an
endemic area but were PCR or slide negative, suggesting
that isolated positive serology may signify persistent low
density parasitaemia below the detection threshold of
conventional (i.e., low blood volume) PCR techniques
which is approximately 1 parasite/μL. Given these uncer-
tainties many blood transfusion services opt for a con-
servative policy of excluding donors who have lived in
malaria-endemic areas.
Transmissibility of sub-microscopic Plasmodium
falciparum infections
There is good evidence that chronic sub-patent infections
are a source of onward mosquito transmission of malaria.
In semi-immune individuals with persistent infections,
gametocytaemia at densities below the limit of microscopy
detection is often infectious [14]. In 1931 in South Africa,
Swellengrebel estimated that crescent densities of only 1:
5,100 leucocytes were sufficient to infect anopheline mos-
quitoes and in 1945 Robertson recorded infections at
thresholds below three crescents per 1,000 leucocytes in
Anopheles gambiae in West Africa [5]. Ciuca et al. studied
the infectivity of long-term asymptomatic P. falciparum
malaria to laboratory-bred Anopheles atroparvus following
experimentally induced infections in ten individuals [6].
They observed infectivity rates of 0.7-7% even when no
gametocytes were seen on microscopy examination of
three thick films. Transmission was confirmed up to the
175th day after infection.
Conclusions
These reports show unequivocally that P. falciparum
can survive for extended periods in the human host. The
previously quoted maximum duration of two years should
be revised; 13 years is the maximum confirmed duration
reported to date. The transfusion malaria cases suggest
the parasite continues its erythrocytic life cycle at very low












Adult female with carcinoma; peri-operative blood transfusion in
1958, with fever 7 days post transfusion. Falciparum malaria
diagnosed subsequently (confirmed by microscopy 14 days after
transfusion)
Merchant seaman with trips to malarious areas 1942–7 and
intermittent anti-malarials. History of malaria, most recent in
Solomon Islands in 1953. Back in Australia since April 1957.
Slide positive 15 months
Chojnacki et al.,
USA [22]
60-years-old male with anaemia and myocardial infarction
transfused who developed fever and chills 4 days post transfusion
with falciparum malaria confirmed subsequently
19-years-old soldier, served in Vietnam until 7 months
before blood donation. Had taken prophylaxis. Recalled
short fever episode in Vietnam
>20 slides negative. Sternal





Case 1: 54-years-old American female transfused during aorto-iliac
bypass graft surgery in 1968. Developed fever 13 days post transfusion
with falciparum malaria confirmed by microscopy nine days later. No
relevant travel history





Case 2: 25-years-old female, transfused for post-partum haemorrhage.
Developed fever ~2 weeks later and then severe malaria with coma.
Diagnosis finally made 3 weeks post transfusion.
21-years-old American soldier in Viet Nam 1967–1968. Took
prophylaxis.
Negative microscopy 7 months
Brooks et al.,
USA[24]
56-years-old male with laryngeal carcinoma. Post-surgical transfusion;
no relevant travel history. Died of cerebral malaria about 3 weeks post
operatively.
Nigerian student. Rare P.FT seen finally after
multiple negative smears and a
500 ml phlebotomy.
32 months
Dike, UK [25] Adult male, given blood transfusion after a road traffic accident.
Developed fever 19 days later and falciparum malaria confirmed
24 days after last transfusion
Nigerian student. Asymptomatic Serology positive. 17 months
Seligman et al.,
USA [26]
34-years-old male. End-stage renal failure on haemodialysis, born in
Italy, in USA since 1955. Monthly blood transfusions. Developed
falciparum malaria in 1970 with symptoms 7 days post transfusion.
No relevant travel history.
Ghanaian, immigrated to USA in Oct 1969. No history of
malaria.
One P.FT ring form found on




No details* No details No details 16 months
Besson et al.,
France [28]
30-years-old male. Orthopaedic surgical procedure (correction of
pseudarthrosis) with transfusion in 1973. Fever 2 weeks later.
Eventual microscopy diagnosis of falciparum malaria. Had never left
France and no history of malaria.
Donor born in Senegal, living in France since 1960, no
history malaria.
Serology (IF) positive 13 years
Saleun et al.,
France [29]
No details. P. falciparum transmitted by blood transfusion Donor from Burkina Faso No details 16 months
Duperval et al.,
Canada [30]
8-years-old Canadian male, treated for chronic lymphocytic
leukaemia, admission with high fever. Cerebral malaria diagnosed
post-mortem, including sequestration of parasitised erythrocytes in
cerebral vasculature. Last recorded blood transfusion was post
gastrectomy 12 years earlier. No travel; route/time of malaria
acquisition unknown. 50% parasitaemia on pre-mortem slides
examined retrospectively.



















Table 1 Transfusion or transplant transmitted falciparum malaria occurring at least six months after the donor’s last exposure risk (Continued)
Babinet et al.,
France [31]
53-years-old Portuguese female with left ventricular insufficiency,
admitted for heart transplant. Developed symptoms of malaria
12 days post op, diagnosed on day 18. She died 4 days later**
51-years-old female originally from Cameroon Donor's serum tested
retrospectively was positive for




65-years-old female, transfused at cardiothoracic surgery (for
rheumatic mitral stenosis) in 1982. Developed post transfusion
falciparum malaria with 5% parasitaemia diagnosed by microscopy
16 days post surgery. No relevant travel history.
Ghanaian male residing in USA for 6 years. Last trip to
Ghana the year prior to donation
Positive P.F serology 10 months
Stickland et al.,
Australia [33]
83-years-old female with myelodysplastic syndrome; transfusion
dependent. 1991: developed falciparum malaria 23 days post-
transfusion diagnosed by microscopy of blood and bone marrow
aspirate. No relevant travel history.
Donor was previously a long-term resident of Papua New
Guinea.
No laboratory confirmation 8 months
Slinger et al.,
Canada [34]
Case 1: 62-years-old female, post transfusion falciparum malaria in
1997. No history of travel to malarious area
Donor 1: 19-years-old female from Ghana originally and
living in Canada for 4 years.
Unable to get a sample for
screening
4 years
Case 2: 24-years-old female developed fever 15 days post transfusion
with P. falciparum confirmed 3 days later
Donor 2: male, originally from Mali. History of malaria
treated with chloroquine in 1991
Donor 2: PCR positive for P.F 4 years
Case 3: 63-years-old male, P. falciparum malaria 16 days after
platelet transfusion









70-years-old male with ischaemic heart disease and aortic aneurysm,
transfused peri-operatively in 1999. Developed post-transfusion
falciparum malaria with symptoms 2 weeks post-op (confirmed by
microscopy 1 week later) and died.
30-years-old male born in Cameroon, with history of malaria
aged 15 years. Moved to Europe 10 years before blood
donation. Last trip to Cameroon 6 years before.






69-years-old male, transfused in 2003 following upper
gastrointestinal bleed. No relevant travel history. Re-admitted 2–3
weeks post transfusion with falciparum malaria diagnosed by
microscopy.
18-years-old blood donor of Ghanaian origin living in USA
for 11 months. Treated for malaria 2 years previously.





81-years-old male, Type 2 diabetes mellitus, post transfusion
cerebral malaria and death in 2002. Symptoms developed 2 weeks
post transfusion. No travel to an endemic area for 20 years.
19-years-old female, originally from sub-Saharan Africa. Liv-
ing in France for 4 years
Positive PCR for P.falciparum
and negative thick film' in the





Case 1: 72-years-old female with acute leukaemia, never visited
malarious area. Developed falciparum malaria 13 days after multiple
blood product transfusions (probably from platelet transfusion)
Male, UK born, worked in Africa for 10 years and history of
malaria.
Serology (IFAT) positive 2 years
Case 2: Male with diabetes and Non-Hodgkins Lymphoma, presenting
with falciparum malaria more than 2 weeks after a transfusion.
Travelled to Kenya the year before
Female, Nigerian but UK resident since childhood. Three
trips to Ghana
Serology (EIA and IFAT)
positive
6 months
Case 3: 62-years-old male, fever 4 days post transfusion for gastrointestinal
bleeding in 1997. Served in Egypt in WWII. Otherwise no travel. Died of
cerebral malaria.
19-years-old, Ghanaian female. UK national since aged
6 months. Travelled to Uganda in 1994 travelled to Uganda
for 6 weeks where she reported undiagnosed fever.
Slide negative. Serology (EIA
and IFAT) positive
3 years
Case 4: 51-years-old male with sickle cell anaemia and chronic renal
failure. Post transfusion falciparum malaria in 2003. No history of
travel to malarious area. Left Jamaica for UK in 1957.





















Table 1 Transfusion or transplant transmitted falciparum malaria occurring at least six months after the donor’s last exposure risk (Continued)
MMWR USA
[39]
25-years-old female with sickle cell anaemia, multiple transfusions
in 2007, admitted with falciparum malaria (16% parasitaemia) more
than 1 month post transfusion.
Donor of Nigerian origin in USA since 2001 with no travel in
the intervening period. Hospitalized with fever presumed
malaria in 1988
Serology positive 6 years
MMWR USA
[40]
Case 1: 27-years-old male with fever 3 weeks post blood transfusion.
No travel outside Florida
27-years-old old donor of Nigerian origin in USA since 2004
with no travel in the intervening period. History of malaria
15 years previously
Serology (IFA) positive, PCR
negative
5 years
Case 2: 78-years-old male receiving chemotherapy for lung carcinoma
diagnosed with falciparum malaria after anaemia investigated. Several
blood transfusions in previous 10 months, most recent 2–4 weeks
previously. No travel in the last year.
30-years-old female, lived in East Africa as a child and
travelled to Uganda, China, Brazil 13–17 months before
donating





55-years-old female; cardiac surgery and blood transfusion. Re-admitted
1 month later with falciparum malaria (microscopy and PCR positive).
No recent relevant travel.
21-years-old male, born in Russia, lived in Benin for 17 years
before immigrating to USA. No travel to endemic area in
past 4 years
Slide and RDT neg, Serology





27-years-old Ghanaian female, living in USA since 1972 with end
stage renal failure. Developed post-transplant falciparum malaria
2 weeks after receiving live related transplant from her mother.
Treated, rejected kidney, graft nephrectomy. Second transplant a
year later (cadaveric). Post transplant falciparum malaria 5 months
later.
Donor 1 (mother)- from Ghana Donor 1 (mother): serology
positive
23 months
Donor 2: no information Donor 2: serology negative


















































































Figure 2 Cases of transfusion or late-presenting clinical malaria show
case. A Transfusion-transmitted falciparum malaria B Non-transfusion cases
Figure 1 Relationship between size of parasite inoculum and
time to microscopy detection.
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This is a common pattern for malaria parasites in all ani-
mals, and is the most likely explanation for persistence of
both P. falciparum and P. malariae in man. There is no
evidence for protracted dormancy or an exo-erythrocytic
parasite stage of these parasites, although it is possible that
the entire life cycle could take place in the vascular spaces
in the placenta or spleen. Incomplete antimalarial drug
treatment may have a modulatory effect on the infection
early on. As well as the poorly understood host’s response
to the parasite, P. falciparum possesses sophisticated im-
mune evasion mechanisms, notably the differential serial
expression of var genes encoding for PfEMP1, the major
surface antigen of the blood stage [65]. How P. falciparum
parasites survive for prolonged periods in the human host15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Case
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Case
ing minimum interval since last malaria exposure of donor or
.
Table 2 Non-transfusion cases of delayed presentation of falciparum malaria
Author, country, reference Case description Time interval since last
infection or exposure
Nagley et al., UK [43] 49-years-old male, British soldier, in India from 1919 to 1928. History of malaria
in India and one unconfirmed “relapse”. Self-treated with quinine in 1932.
No other relevant travel, or blood transfusions. Developed jaundice and then
severe malaria in 1945. P. falciparum trophozoites and gametocytes on
microscopy
13-17 years
Walters et al., UK [44] 21-years-old pregnant female, originally from Nigeria. Asymptomatic.
Diagnosis made by microscopy performed to investigate abnormal routine
antenatal full blood count in 1958
19 months
Russell et al., USA [45] Medical student with annual episodes of smear positive falciparum malaria for
4 years after return from the Belgian Congo in 1934. Eventually cleared
following a prolonged course of quinine
4 years
Revel et al., France [46] 7-years-old male, originally from Comoros islands presenting with a febrile
illness. P. falciparum trophozoites and gametocytes seen on microscopy,
mixed with P. ovale.
3 years
Kyronseppa et al., Finland [47] 46-years-old male sailor, last travel to endemic area was Jeddah 20 months
previously. Other possible occupational exposure in late 1970s. Presented with
fever after head injury (intracerebral bleed). P. falciparum diagnosed by
microscopy
20 months
Krajden et al., Canada [48] 30-years-old male, originally from Ghana. Presented with diabetic ketoacidosis.
Malaria diagnosed by microscopy. Serology positive.
32 months
MMWR USA [49] Obstetrician/gynaecologist admitted with fever. Last trip to a malarious area
was 15 years before (Afghanistan). Diagnosed on microscopy. Labelled as
cryptic malaria (occupational exposure cannot be excluded).
15 years (unless occupational
exposure)
Howden et al., Australia [16] 28-years-old female, born in Eritrea and then lived in Sudan. Post
splenectomy malaria. Pre-operative slides negative. Retrospective histological
diagnosis of hyperreactive malarial splenomegaly.
9 years
Giobbia et al., Italy [50] 29-years-old pregnant woman. Originally from Ghana but living in Italy for
9 years. Last trip to Ghana 4 years previously. Presented with fever and vomiting.
Positive P. falciparum rapid diagnostic test, microscopy and serology.
4 years
Lesko et al., USA [51] Congenital falciparum malaria in the infant of a mother who had not been in
Haiti for 7 years
7 years
Greenwood et al., Sweden [52] 18-years-old male with sickle-cell anaemia, born in Togo, living in Sweden for
14 years. Last visit 4 years previously. Presented with fever. Microscopy, RDT
and PCR positive for P. falciparum.
4 years
D’Ortenzio et al., France [53] 11 cases summarized as part of a case–control study (variable level of detail):
26-years-old male, born in France and lived in Madagascar for 2 years where
he took regular chloroquine + primaquine prophylaxis. Presented with severe
malaria 7 months after return
7 months
5 cases (2 HIV+) with >1 year time lapse since arrival in France >1 year
5 pregnant women >3 years
Theunissen et al., Belgium [54] 30-years-old male, originally from Guinea-Conakry and moved to Belgium
9 years earlier. No other travel of note. Friend from Guinea stayed with him
2 weeks earlier (raises possibility of ‘baggage malaria’).
9 years
Foca et al., Italy [55] 60-years-old Italian engineer, worked in Tanzania for 33 years where he was
treated for malaria. Returned to Italy January 2006 and was diagnosed with
carcinoma of the lung and splenomegaly. Fever episode 11 months after
return to Italy which resolved spontaneously and P. falciparum gametocytes
seen on a blood smear 1 month later.
11 months
Szmitko et al., Canada [56] 29-years-old Angolan female. Immigrated to Canada in 1999, no relevant
travel in intervening period. History of treated malaria in Angola. Presented
with fever. Falciparum malaria diagnosed by microscopy and PCR.
8 years
MMWR USA [41] Case 1: 17-years-old female, USA born, Ghanaian mother, last travel 4 years
previously (report implies to Ghana but not stated explicity). Admitted to
hospital with falciparum malaria. No details on diagnosis
4 years
Case 2: 31-years-old female, presented to the emergency department with
severe falciparum malaria (10% parasitaemia). Travelled to Nicaragua in 2008;
took prophylaxis.
2 years
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Table 2 Non-transfusion cases of delayed presentation of falciparum malaria (Continued)
MMWR USA [57] 8-years-old female, originally from Nigeria. Moved to USA 2007, one trip back
in 2008. Malaria history not documented. Presented symptomatic to USA
hospital. P. falciparum diagnosis confirmed by microscopy and PCR.
3 years
Monge-Maillo et al., Spain [58] 3 cases: No details on clinical presentation or diagnosis. Only age, sex and
country of probably acquisition
Case 1 : 32 -years-old male, Angola 13 months
Case 2 : 17-years-old male, Senegal 14 months
Case 3 : 28-years-old male, Guinea 28 months
Berrevoets et al., Netherlands
[59]
48-years-old male, born in Burkina Faso, immigrated to Netherlands 8 years
previously, last travel to an endemic country 2.5 years previously. Last
anti-malarial drugs in 1997. Admitted with severe malaria confirmed by RDT,
microscopy (P. falciparum trophozoites and schizonts) and PCR.
2.5 years
RDT: rapid diagnostic test, PCR: polymerase chain reaction, IFA: indirect fluorescent antibody assay.
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is unclear. The appearance of symptoms years after in-
fection may reflect waning of host immunity. The late re-
crudescing infections presented in Table 2 were associated
with concomitant conditions, which may have led to im-
munosuppression in several cases, e.g., diabetes mellitus,
malignancy, and pregnancy.
It is not possible to estimate how common chronic in-
fection with P. falciparum might be. The World Malaria
Report estimated that in 2012 there were between 135
and 287 million malaria cases of which 91% were caused
by P. falciparum [66]. Even if only a tiny proportion of
untreated or partially treated infections become indo-
lent, this represents a huge potential reservoir of sus-
tained transmission.
Approximately 107 million units of blood donations are
collected globally every year [67]. Very few blood transfu-
sion services perform routine malaria antibody testing,
with most non-endemic countries relying on deferral of
donors considered to be at risk. This appears to be very
effective in preventing the vast majority of cases of
transfusion-transmitted malaria [68]. It is also possible
that some transfusion-transmitted parasites do not cause
disease. A large proportion of the transfusion-recipients
presented in Table 1 were older, with co-morbidities such
as malignancy, diabetes, end-stage renal failure, and
sickle-cell anaemia and thus may have been more suscep-
tible to malaria following inoculation of very low numbers
of parasites than immunocompetent recipients. The re-
quirement for blood transfusion indicates anaemia and
therefore illness. Furthermore, blood transfusion itself is
associated with immunosuppression [69]. The incidence
of transfusion-transmitted malaria in endemic countries is
probably far higher than realised since screening by
microscopy only is usually the method used to select
donors and antimalarial drugs are not added to blood
donations. Transfusion malaria could become an im-
portant source of malaria within countries where there
is incomplete elimination.These observations on the longevity of falciparum infec-
tions and the sub-microscopic parasite burden are relevant
to immigrants and refugees who have left malarious areas.
In a parasite prevalence study of 195 African refugees in
Italy in 2007, 62 patients tested positive for malaria using
molecular detection methods, of whom 13 were gameto-
cytaemic. Microscopy confirmed the positive results in 14
of the 62 cases, of which 13 were P. falciparum [70]. The
reported prevalence of asymptomatic malaria in refugees
screened post-arrival ranges from 2.4 to 31.8%, depending
on the population and the method of diagnosis. Where
malaria vectors are present these people may act as a
source of transmission. The possibility that asymptomatic
infections with artemisinin-resistant falciparum malaria
could be imported from Southeast Asia to Africa is a
current concern.
In countries targeting malaria elimination, achieving this
aim is likely to take longer if the sub-microscopic parasites
are not eliminated. Improved high-throughput and low-
cost methods are needed to detect these individuals har-
bouring low parasite densities. Conventional PCR methods
still miss infections with densities below 1/uL. Serology has
been proposed as a useful tool to detect changes in malaria
transmission in settings where transmission is in decline
and appears to be a sensitive method for the detection of
malaria infection but its specificity is unclear, as is the usual
duration of detectable antibodies once an infection has
cleared. There is a need to investigate the role of serology
in defining asymptomatic carriage, certainly in lower trans-
mission and pre-elimination countries.
Plasmodium falciparum can persist in the human host
for longer than thought previously. Current policies in
malaria-free countries of excluding blood donors who
have lived in malarious areas are justified. Vigilance for
longer than three years after declaring elimination in an
area may be needed.Competing interests
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